Survival for follicular lymphoma and diffuse large B-cell lymphoma is improving in Europe, according to a recent study published online ahead of print in the journal The Lancet Haematology; however, variation in survival remains between European regions.1
Because treatment of non-Hodgkin lymphoma has vastly changed, thereby benefiting patients with follicular lymphoma and diffuse large B-cell lymphoma, researchers sought to compare dynamics of cancer mortality in patients with those 2 types of lymphoma in 5 large European areas.
For the study, researchers analyzed data from 13 988 follicular lymphoma and 25 320 diffuse large B-cell lymphoma cases in patients older than 15 years diagnosed between 1996 and 2004 in 1 of 5 areas (Scotland and Wales, and northern, central, eastern, and southern Europe).
Results showed that for follicular lymphoma, 5-year net survival improved from 1999-2001 to 2002-2004 in northern, central, southern, and eastern Europe. For diffuse large B-cell lymphoma, 5-year net survival improved in Scotland and Wales, and northern, central, and southern Europe.
Researchers noted the largest area disparity during the 2002-2004 period between eastern Europe and northern Europe.
“Although survival for follicular lymphoma and diffuse large B-cell lymphoma is improving, the results from this study should foster the search for more and better means of improvement of access to adequate care than that at present,” the authors conclude.
“Study of the dynamics of the excess mortality rate seems to be a useful clinical indicator to help the practitioner’s choice of optimum management of patients.”
1. Mounier M, Bossard N, Remontet L, et al. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5) [published online ahead of print October 22, 2015]. Lancet Haematol. doi:10.1016/S2352-3026(15)00155-6.